ARTICLE | Distillery Therapeutics
A DC membrane-based vaccine for solid tumors
July 5, 2022 9:08 PM UTC
A genetically engineered, cell membrane-based nanovesicle vaccine that integrates personalized antigen presentation and checkpoint blockade could help treat solid tumors. The vaccine consisted of nanovesicles derived from dendritic cells (DCs) that expressed an anti-PD1 mAb on their cell surface, and were infected with a recombinant adenovirus encoding tumor neoantigens that were presented on MHCI after the DCs matured...